References
- LeeCTCondeBJMazlanMSwitching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia PacificJ Clin Psychiatry200263756957612143912
- LiebermanJAStroupTSMcEvoyJPClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) InvestigatorsEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
- MasandPSBerrySLSwitching antipsychotic therapiesAnn Pharmacother200034220020710676829
- NyhuisAWFariesDEAscher-SvanumHStaufferVLKinonBJPredictors of switching antipsychotic medications in the treatment of schizophreniaBMC Psychiatry2010107520920179
- WeidenPJYoungAHBuckleyPFThe art and science of switching of antipsychotic medications, part 1J Clin Psychiatry20066711e1517201045
- WeidenPJDiscontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trialJ Clin Psychiatry200768Suppl 1121917286523
- GolebiewskiKAntipsychotic switching: when, how, why?Graylands Hospital Drug Bulletin200614114
- Schering-PloughEfficacy and safety of asenapine compared with olanzapine in patients with persistent negative symptoms of schizophrenia (A7501013) (COMPLETED) (P05771)ClinicalTrials.govBethseda, MDUS National Library of Medicine2010 [updated April 8, 2010]. Available from: http://clinicaltrials.gov/ct2/show/NCT00145496. NLM identifier: NCT00145496Accessed April 19, 2012
- Schering-PloughEfficacy and safety of asenapine compared with olanzapine in patients with persistent negative symptoms of schizophrenia 25543) (COMPLETED) (P05817)ClinicalTrials.govBethseda, MDUS National Library of Medicine2010 [updated October 2, 2009]. Available from: http://clinicaltrials.gov/ct2/show/NCT00212836. NLM identifier: NCT00212836Accessed April 19, 2012
- BuchananRPanagidesJKouassiASzegediAAsenapine versus olanzapine in patients with predominent persistent negative symptoms of schizophreniaSchizophrenia Research20081022252
- HesterEKThrowerMRCurrent options in the management of olanzapine- associated weight gainAnn Pharmacother200539230231015632224
- MukundanAFaulknerGCohnTRemingtonGAntipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problemsCochrane Database Syst Rev201012CD00662921154372
- NewcomerJWAntipsychotic medications: metabolic and cardiovascular riskJ Clin Psychiatry200768Suppl 481317539694
- US Food and Drug AdministrationFDA drug safety communication: serious allergic reactions reported with the use of Saphris (asenapine maleate)Rockville, MDUS Food and Drug Administration2011 Available from: http://www.fda.gov/Drugs/DrugSafety/ucm270243